AU2003241384A1 - Cyclic peptide anti-viral agents and methods - Google Patents

Cyclic peptide anti-viral agents and methods

Info

Publication number
AU2003241384A1
AU2003241384A1 AU2003241384A AU2003241384A AU2003241384A1 AU 2003241384 A1 AU2003241384 A1 AU 2003241384A1 AU 2003241384 A AU2003241384 A AU 2003241384A AU 2003241384 A AU2003241384 A AU 2003241384A AU 2003241384 A1 AU2003241384 A1 AU 2003241384A1
Authority
AU
Australia
Prior art keywords
methods
cyclic peptide
viral agents
peptide anti
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003241384A
Other versions
AU2003241384A8 (en
Inventor
M. Reza Ghadiri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2003241384A8 publication Critical patent/AU2003241384A8/en
Publication of AU2003241384A1 publication Critical patent/AU2003241384A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU2003241384A 2002-05-06 2003-05-06 Cyclic peptide anti-viral agents and methods Abandoned AU2003241384A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37825602P 2002-05-06 2002-05-06
US60/378,256 2002-05-06
PCT/US2003/014372 WO2003092631A2 (en) 2002-05-06 2003-05-06 Cyclic peptide anti-viral agents and methods

Publications (2)

Publication Number Publication Date
AU2003241384A8 AU2003241384A8 (en) 2003-11-17
AU2003241384A1 true AU2003241384A1 (en) 2003-11-17

Family

ID=29401596

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003241384A Abandoned AU2003241384A1 (en) 2002-05-06 2003-05-06 Cyclic peptide anti-viral agents and methods

Country Status (2)

Country Link
AU (1) AU2003241384A1 (en)
WO (1) WO2003092631A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566765B2 (en) 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
WO2010051667A1 (en) * 2008-11-10 2010-05-14 复旦大学 Pharmaceutical compositions comprising cyclic peptide nanotubes and the uses thereof
SG11201500111VA (en) 2012-08-29 2015-03-30 Agency Science Tech & Res Peptides and uses thereof
JP2016516752A (en) * 2013-04-02 2016-06-09 ザ スクリプス リサーチ インスティテュート Use of cyclic peptides for the treatment and prevention of atherosclerosis
PT3149025T (en) 2014-05-21 2019-08-01 Entrada Therapeutics Inc Cell penetrating peptides and methods of making and using thereof
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
US10456443B2 (en) 2014-08-27 2019-10-29 Ohio State Innovation Foundation Peptidyl calcineurin inhibitors
CN111867616A (en) * 2018-01-11 2020-10-30 国立大学法人东京大学 NTCP inhibitors
EP3749365A4 (en) 2018-01-29 2022-01-12 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
EP3755351A4 (en) 2018-02-22 2021-11-24 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy

Also Published As

Publication number Publication date
WO2003092631A3 (en) 2005-04-28
WO2003092631A2 (en) 2003-11-13
AU2003241384A8 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
AU2003212458A1 (en) Cyclo(n)pyrroles and methods thereto
AU2003270652A1 (en) Protein and peptide expression for passive immunity
AU2003216221A1 (en) Attachment and articles using same
AU2003290563A1 (en) Leptin-related peptides
AU2003232077A1 (en) Cyclic peptide anti-cancer agents and methods
AU2003241384A1 (en) Cyclic peptide anti-viral agents and methods
AU2003211163A1 (en) Partial peptide mimetics and methods
AU2003207744A1 (en) Transport peptides and uses therefor
IL165112A0 (en) Variant integrinpolypeptides and thereof
AU2003272423A1 (en) Centrosome proteins and uses thereof
AU2003290886A1 (en) Modified alpha-msh peptides and derivatives thereof
AU2003231827A1 (en) Pseudo-tissues and uses thereof
AU2003298511A1 (en) Retroyclins: antiviral and antimicrobial peptides
AU2003207628A1 (en) Structural and cytoskeleton-associated proteins
AU2003252075A1 (en) Human immunosuppressive protein
AU2003218232A1 (en) Peptide analogues and uses thereof
AU2003302173A1 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003220265A1 (en) Tamperproof and counterfeit-resistant structure
AU2003280992A1 (en) Novel proteins and use thereof
AU2003292774A1 (en) Novel proteins and use thereof
AU2003291426A1 (en) Gp64-pseudotyped vectors and uses thereof
AU2003216442A1 (en) Enkurin and uses thereof
AU2002951912A0 (en) Tryptase polypeptide and uses thereof
EP1699809A4 (en) Amniotic-derived peptide and uses thereof
AU2003228397A1 (en) HAUSP-p53 INTERACTION AND USES THEREOF

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase